Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Oct 7;2:15019. doi: 10.1038/mto.2015.19

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Official journal of the American Society of Gene & Cell Therapy

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Cell cycle profiles of human hepatoma cells undergoing epi-virotherapeutic cotreatment with resminostat and MeV-SCD: human hepatoma cell lines HepG2, Hep3B, and PLC/PRF/5 were infected with MeV-SCD (MeV) or mock infected (MOCK) and resminostat (Res) was added at 3 hpi or not. Intracellular DNA was stained with propidium iodide (PI) at 96 hpi and measured by flow cytometry. Combinatorial treatment (Res + MeV) was found to enhance the population of hypoploid/apoptotic cells (black vertical bars: sub2N) compared to corresponding single agent treatments (Res or MeV); concurrently, fractions of proliferating cells (represented in cell cycle phases S and G₂) were found to diminish. Means of three independent experiments carried out in duplicates or triplicates are shown. P values of one-way ANOVA with a Tukey posttest.